Olivia's Feed
Oct 22, 2014

Exclusive: Advent, Avista near deal for UCB’s Kremers Urban – sources

By Olivia Oran and Greg Roumeliotis

(Reuters) – A consortium of buyout firms Advent International Corp and Avista Capital Partners is in advanced talks to acquire UCB SA’s (UCB.BR: Quote, Profile, Research, Stock Buzz) U.S. generic drugs unit Kremers Urban Pharmaceuticals Inc, according to people familiar with the matter.

Advent and Avista have prevailed in an auction for Kremers Urban, which attracted interest from other private equity firms as well as specialty drugmaker Akorn Inc (AKRX.O: Quote, Profile, Research, Stock Buzz), the people said this week.

Oct 22, 2014

Advent, Avista near deal for UCB’s Kremers Urban-sources

Oct 22 (Reuters) – A consortium of buyout firms Advent
International Corp and Avista Capital Partners is in advanced
talks to acquire UCB SA’s U.S. generic drugs unit
Kremers Urban Pharmaceuticals Inc, according to people familiar
with the matter.

Advent and Avista have prevailed in an auction for Kremers
Urban, which attracted interest from other private equity firms
as well as specialty drugmaker Akorn Inc, the people
said this week.

Oct 20, 2014

Exclusive: Vitamin Shoppe in talks to hire bank amid activist pressure – sources

By Olivia Oran and Greg Roumeliotis

(Reuters) – Vitamin Shoppe Inc (VSI.N: Quote, Profile, Research, Stock Buzz), the nutritional supplement retailer under activist shareholder pressure to consider a sale, is speaking to investment banks about hiring a financial adviser, according to people familiar with the matter.

The scope of a bank’s mandate is not yet clear, and Vitamin Shoppe may decide against such a move, the sources said on Monday. However, the talks illustrate the retailer is trying to formulate a response to requests made by some big shareholders.

Oct 20, 2014

Top Allergan holder Paulson urges deal with Shire -sources

Oct 20 (Reuters) – Allergan Inc shareholder Paulson
& Co is urging the Botox maker to merge with specialty
pharmaceutical company Shire Plc as an alternative to a
deal with hostile bidder Valeant Pharmaceuticals International
Inc, according to two people familiar with the matter.

The hedge fund, which earlier supported a deal with Valeant,
told Allergan CEO David Pyott that it would now support a deal
with Shire, the sources said. It was not immediately clear
whether Allergan would pursue such a deal.

Oct 20, 2014

Exclusive: Allergan shareholder Paulson & Co urges deal with Shire – sources

By Olivia Oran

(Reuters) – Allergan Inc (AGN.N: Quote, Profile, Research, Stock Buzz) shareholder Paulson & Co is urging the Botox maker to merge with specialty pharmaceutical company Shire Plc (SHP.L: Quote, Profile, Research, Stock Buzz) as an alternative to a deal with hostile bidder Valeant Pharmaceuticals (VRX.TO: Quote, Profile, Research, Stock Buzz), according to two people familiar with the matter.

   The hedge fund told Allergan CEO David Pyott that it would support a deal with Shire, the sources said. The deal would not be structured as a so-called tax inversion, the people said.

Oct 20, 2014

Allergan shareholder Paulson & Co urges deal with Shire -sources

Oct 20 (Reuters) – Allergan Inc shareholder Paulson
& Co is urging the Botox maker to merge with specialty
pharmaceutical company Shire Plc as an alternative to a
deal with hostile bidder Valeant Pharmaceuticals,
according to two people familiar with the matter.

The hedge fund told Allergan CEO David Pyott that it would
support a deal with Shire, the sources said. The deal would not
be structured as a so-called tax inversion, the people said.

Oct 14, 2014

Brazilian steakhouse Fogo de Chão taps banks for IPO -sources

Oct 14 (Reuters) – Fogo de Chão, the Brazilian steakhouse
restaurant chain known for its all-you-can-eat meat tableside
service, has hired underwriters for a potential initial public
offering (IPO), according to people familiar with the matter.

JPMorgan Chase & Co and Jefferies Group LLC have
been assigned lead roles in the IPO, which may come next year
and value the company, owned by buyout firm Thomas H. Lee
Partners LP, at as much as $1 billion, including debt, the
people said on Tuesday.

Sep 22, 2014

Allergan revives talks to acquire Salix: source

NEW YORK (Reuters) – Allergan Inc (AGN.N: Quote, Profile, Research, Stock Buzz) has revived discussions to buy Salix Pharmaceuticals Ltd (SLXP.O: Quote, Profile, Research, Stock Buzz), a person familiar with the matter said on Monday, asking not to be identified because the talks are confidential.

The exact status of the discussions between the two drugmakers could not be immediately established. Spokesmen for Allergan and Salix declined to comment.

Sep 18, 2014

Exclusive: Vitamin Shoppe gets investor push to sell itself – sources

NEW YORK (Reuters) – A handful of large shareholders are calling on nutritional supplement retailer Vitamin Shoppe Inc (VSI.N: Quote, Profile, Research, Stock Buzz) to consider a sale to private equity or larger rival GNC Holdings Inc (GNC.N: Quote, Profile, Research, Stock Buzz), according to people familiar with the matter.

At least one activist fund has accumulated a position and has held conversations with members of the Vitamin Shoppe board about a potential sale, the people said, asking not to be named because the matter is not public. It is considering whether to go public with its push, the people added.

Sep 16, 2014

Exclusive: Top investors push Salix to abandon Cosmo deal – sources

NEW YORK (Reuters) – A number of top 20 investors at Salix Pharmaceuticals Ltd (SLXP.O: Quote, Profile, Research, Stock Buzz) are threatening to vote down the company’s proposed deal to buy a unit of Cosmo Pharmaceuticals (COPN.S: Quote, Profile, Research, Stock Buzz) and are pressing Salix to consider selling itself instead, people familiar with the matter said on Tuesday.

Raleigh, North Carolina-based Salix, which makes drugs for gastrointestinal disorders, said in July it would merge with Cosmo’s Irish subsidiary, a deal that would allow Salix to move its tax domicile abroad in a practice known as inversion.